Key facts
- Goldman Sachs has dropped its stock coverage of Fulcrum Therapeutics.
- The decision follows Fulcrum Therapeutics' announcement to halt its clinical trial.
Goldman Sachs has made the decision to discontinue its stock coverage of Fulcrum Therapeutics. This action was taken subsequent to Fulcrum Therapeutics' announcement that it would be halting its ongoing clinical trial.